Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Abstract Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF). However, no clear survival benefit has been demonstrated, which may in part reflect suboptimal...

Full description

Bibliographic Details
Main Authors: Novella Pugliese, Claudia Giordano, Davide Nappi, Luigiana Luciano, Claudio Cerchione, Mario Annunziata, Beniamino Casale, Elena Crisà, Maria Rosaria Villa, Luca Pezzullo, Maria Iovine, Marco Picardi, Francesco Grimaldi, Fabrizio Pane, Vincenzo Martinelli
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:Cancer Medicine
Subjects:
hydroxyurea
Janus kinase (JAK) inhibitors
primary myelofibrosis
ruxolitinib
Online Access:https://doi.org/10.1002/cam4.2147

Internet

https://doi.org/10.1002/cam4.2147

Similar Items